Utility of PET/neck MRI digital fusion images in the management of recurrent or persistent thyroid cancer.

BACKGROUND Approximately 30% of thyroid cancer patients present with reappearing disease within 40 years of initial diagnosis. Hence, sensitive postsurgical monitoring techniques are imperative to successful long-term care. The objective of this study was to assess the added clinical utility of a combined positron emission tomography/magnetic resonance imaging (PET/MRI) of the neck in conjunction with standard imaging in the detection of recurrent thyroid carcinoma. We define standard imaging as a neck sonogram, 131I scan, computed tomography, and MRI. METHODS This study included 34 patients treated for thyroid cancer at Washington Hospital Center. All patients had previously undergone near-total or total thyroidectomy, standard follow-up imaging studies, and laboratory studies. Twenty-nine of thirty-four patients had received at least one 131I treatment prior to the study. Each patient received a PET and MRI scan, and these images were subsequently digitally fused. RESULTS Individually and blinded, four endocrinologists retrospectively reviewed all information in patient charts prior to PET and PET/MRI coregistration. A clinical assessment and treatment plan were devised with these data. Following the initial assessment, the endocrinologists were provided results from the PET and PET/MRI fusion studies and asked to make a revised assessment and treatment plan. For each patient, the physicians categorized PET/MRI fusion results as providing new information that altered the initial treatment plan, providing new information that confirmed the initial treatment plan, or providing no additional information. On average, PET/MRI coregistration provided additional information that altered the treatment plan in 46% of the cases, provided additional information that confirmed the treatment plan in 36% of cases, and did not provide any additional information in 18% of cases. CONCLUSION The combination of structural and functional data that PET/neck MRI fusion offers provided further information in an overwhelming majority of thyroid cancer patients in this study. Thus PET/MRI can be a useful tool in surgical planning, radioactive iodine therapy decisions, and determining the level of follow-up necessary for each patient.

[1]  S. Jhiang,et al.  Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. , 1994, The American journal of medicine.

[2]  P. Ladenson,et al.  Prospective multicenter study of thyroiscarcinoma treatment: initial analysis of staging and outcome. National Thyroid Cancer Treatment Cooperative Study Registry Group. , 1998, Cancer.

[3]  Louise Davies,et al.  Increasing incidence of thyroid cancer in the United States, 1973-2002. , 2006, JAMA.

[4]  L. Wartofsky Using baseline and recombinant human TSH-stimulated Tg measurements to manage thyroid cancer without diagnostic (131)I scanning. , 2002, The Journal of clinical endocrinology and metabolism.

[5]  J. Shah,et al.  Initial results from a prospective cohort study of 5583 cases of thyroid carcinoma treated in the United States during 1996 , 2000, Cancer.

[6]  R. Kloos,et al.  Current Approaches to Primary Therapy for Papillary and Follicular Thyroid Cancer , 2001 .

[7]  O. Schober,et al.  Fluorine-18 fluorodeoxyglucose positron emission tomography in thyroid cancer: results of a multicentre study , 1999, European Journal of Nuclear Medicine.

[8]  L. Wartofsky Management of Patients with Scan Negative, Thyroglobulin Positive Differentiated Thyroid Carcinoma , 1998 .

[9]  N. D. Charkes,et al.  On the prevalence of familial nonmedullary thyroid cancer in multiply affected kindreds. , 2006, Thyroid : official journal of the American Thyroid Association.

[10]  K. Schmiegelow,et al.  Increased fluorine-18 2-fluoro-2-deoxy-D-glucose (FDG) uptake in childhood CNS tumors is correlated with malignancy grade: a study with FDG positron emission tomography/magnetic resonance imaging coregistration and image fusion. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  K. Burman Micropapillary thyroid cancer: should we aspirate all nodules regardless of size? , 2006, The Journal of clinical endocrinology and metabolism.

[12]  L. Wartofsky Management of low-risk well-differentiated thyroid cancer based only on thyroglobulin measurement after recombinant human thyrotropin. , 2002, Thyroid : official journal of the American Thyroid Association.

[13]  E. Mazzaferri,et al.  Management of papillary and follicular (differentiated) thyroid cancer: new paradigms using recombinant human thyrotropin. , 2002, Endocrine-related cancer.

[14]  P. Yeo,et al.  Pathological tumor-node-metastasis (pTNM) staging for papillary and follicular thyroid carcinomas: a retrospective analysis of 700 patients. , 1997, The Journal of clinical endocrinology and metabolism.

[15]  Gerard M Doherty,et al.  Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. , 2006, Thyroid : official journal of the American Thyroid Association.

[16]  P. Schnyder,et al.  The value of PET, CT and in-line PET/CT in patients with gastrointestinal stromal tumours: long-term outcome of treatment with imatinib mesylate , 2004, European Journal of Nuclear Medicine and Molecular Imaging.

[17]  S. Prato Tackling hyperglycemia: a more comprehensive approach. , 2006 .

[18]  Stephanie L. Lee,et al.  A consensus report of the role of serum thyroglobulin as a monitoring method for low-risk patients with papillary thyroid carcinoma. , 2003, The Journal of clinical endocrinology and metabolism.

[19]  J. Weissman,et al.  MRI Detection of Cervical Metastasis From Differentiated Thyroid Carcinoma , 2001, The Laryngoscope.

[20]  H. Schöder,et al.  Positron emission imaging of head and neck cancer, including thyroid carcinoma. , 2004, Seminars in nuclear medicine.

[21]  P. Som,et al.  Detection of metastasis in cervical lymph nodes: CT and MR criteria and differential diagnosis. , 1992, AJR. American journal of roentgenology.

[22]  P. Ladenson,et al.  The role of PET in follow-up of patients treated for differentiated epithelial thyroid cancers , 2007, Nature Clinical Practice Endocrinology &Metabolism.

[23]  G. V. von Schulthess,et al.  Why most PET of lung and head-and-neck cancer will be PET/CT. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[24]  P. Ladenson,et al.  Prospective multicenter study of thyroid carcinoma treatment , 1998 .

[25]  David Goldenberg,et al.  The Role of Positron Emission Tomography/Computed Tomography in the Management of Recurrent Papillary Thyroid Carcinoma , 2005, The Laryngoscope.

[26]  M. Ringel,et al.  Papillary and follicular variant of papillary carcinoma of the thyroid: Initial presentation and response to therapy , 2005, Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery.

[27]  Carmen C. Solorzano,et al.  Thyroid Cancer: Is the Incidence Still Increasing? , 2004, Annals of Surgical Oncology.

[28]  R. Jeffrey,et al.  Management of thyroid nodules detected at US: Society of Radiologists in Ultrasound consensus conference statement. , 2005, Ultrasound quarterly.

[29]  E. Wardelmann,et al.  Integrated PET/CT in differentiated thyroid cancer: diagnostic accuracy and impact on patient management. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.